YYYa-Ru Yang

Ya-Ru Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ya-Ru Yang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Jin

    Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, the, Ministry of Education, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China

    2 shared publications
  • Chang-Ming Lin

    Department of Urology, the Fourth Affiliated Hospital of Anhui Medical University, Hefei, 230011, China

    1 shared publication
  • Chao Li

    The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, 230032, China

    1 shared publication
  • Chao Shi

    The First Affiliated Hospital of Bengbu Medical College

    1 shared publication
  • Chuchu Hu

    Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China

    1 shared publication
  • Fan-Xu Kong

    School of Pharmacy, Anhui Medical University, Hefei 230032, China; The Second People's Hospital of Hefei, Hefei 230011, Anhui, China

    1 shared publication

Latest Publications

  • Protocatechualdehyde protects against acute liver injury by inhibiting RIPK1-mediated necroptosis and IFN-γ/JAK1/STAT1 axis

    by Chuchu Hu, Yijia Miao, Wenjing Yan, Mengyi Jia, Xiaoya Zhang, Mengjuan Li, Xiaolong Sun, Ziyi Liu, Jun Li, Haidi Li, et al.

  • Open Access

    Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2‐Dependent Mechanisms in Hyperuricemic Nephropathy

    by Tong Zu, Hang Yang, Jie Wang, Shuangjian Li, Yue Yu, Kuo Zhang, Xiuxiu Song, Jie Ying, Yaru Yang, Xian Wang, et al.

    Hyperuricemia has been linked to kidney problems including hyperuricemic nephropathy (HN), which is characterised by inflammation and fibrosis in the kidneys. HN is frequently observed in patients with chronic gout. However, the causes of HN are not fully understood and effective treatments are limited. The status of RNA m6A, expression, and location of METTL3 in the kidney was evaluated in mice with HN. The mechanism of the METTL3‐associated ABCG2 downregulation was further studied in mTEC cells and a potassium oxazinate + adenine‐induced mice model and adeno‐associated virus 9 (AAV9)‐mediated METTL3 silencing mice. Expressions of ABCG2, α‐SMA, collagen‐1, TGF‐β1, IL‐1β, IL‐6, and TNF‐α were analysed using real‐time PCR and western blotting. Hyperuricemia led to elevated m6A levels and METTL3 expression in mouse kidneys. METTL3 was mainly located in mTEC cells. METTL3‐specific inhibitor STM2457 alleviated uric acid‐induced inflammatory and fibrotic responses in mTEC cells. Mechanistically, ABCG2 was identified as a target of METTL3 by RNA sequencing. The stability of ABCG2 was decreased through the binding of IGF2BP2 (insulin‐like growth factor 2 binding protein 2) to its m6A‐modified stop codon regions. Silencing or inhibition of METTL3 significantly reduced uric acid‐induced cell injury and increased ABCG2 expression, leading to uric acid excretion. In vivo data showed that AAV9‐mediated METTL3 silencing significantly alleviated renal dysfunction and fibrosis in HN mice. Our study provides the first evidence that METTL3 regulates uric acid excretion by controlling the m6A levels of ABCG2 through the binding of IGF2BP2, and inhibiting METTL3 can effectively alleviate kidney damage caused by hyperuricemia, showing potential as a therapy for HN.


  • RG108 attenuates acute kidney injury by inhibiting P38 MAPK/FOS and JNK/JUN pathways

    by Fan-Xu Kong, Hui Liu, Tao Xu, Shuang-Jian Li, Wei Li, Hao Lu, Nan-Nan Ma, Yun-Long Wang, Ji-Hong Shi, Ya-Ru Yang, et al.


  • Open Access

    Epigallocatechin Gallate Attenuates Gentamicin-Induced Nephrotoxicity by Suppressing Apoptosis and Ferroptosis

    by Lin Yue, Ya-Ru Yang, Wen-Xian Ma, Hong-Yan Wang, Qian-Wen Fan, Yue-Yue Wang, Chao Li, Jing Wang, Zi-Mu Hu, Xue-Fu Wang, et al.

    Gentamicin (GEN) is a kind of aminoglycoside antibiotic with the adverse effect of nephrotoxicity. Currently, no effective measures against the nephrotoxicity have been approved. In the present study, epigallocatechin gallate (EG), a useful ingredient in green tea, was used to attenuate its nephrotoxicity. EG was shown to largely attenuate the renal damage and the increase of malondialdehyde (MDA) and the decrease of glutathione (GSH) in GEN-injected rats. In NRK-52E cells, GEN increased the cellular ROS in the early treatment phase and ROS remained continuously high from 1.5 H to 24 H. Moreover, EG alleviated the increase of ROS and MDA and the decrease of GSH caused by GEN. Furthermore, EG activated the protein levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). After the treatment of GEN, the protein level of cleaved-caspase-3, the flow cytometry analysis and the JC-1 staining, the protein levels of glutathione peroxidase 4 (GPX4) and SLC7A11, were greatly changed, indicating the occurrence of both apoptosis and ferroptosis, whereas EG can reduce these changes. However, when Nrf2 was knocked down by siRNA, the above protective effects of EG were weakened. In summary, EG attenuated GEN-induced nephrotoxicity by suppressing apoptosis and ferroptosis.


  • Open Access

    Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering

    by Hong Zhou, Xu-Dong Zheng, Chang-Ming Lin, Jie Min, Shuang Hu, Ying Hu, Liang-Yun Li, Jia-Si Chen, Yu-Min Liu, Hao-Dong Li, et al.

    Prostate cancer (PC) is the most common carcinoma among men worldwide which results in 26% of leading causes of cancer-related death. However, the ideal and effective molecular marker remains elusive. CircRNA, initially observed in plant-infected viruses and Sendai virus in 1979, is generated from pre-mRNA back-splicing and comes in to play by adequate expression. The differential expression in prostate tissues compared with the control reveals the promising capacity in modulating processes including carcinogenesis and metastasis. However, the biological mechanisms of regulatory network in PC needs to systemically concluded. In this review, we enlightened the comprehensive studies on the definite mechanisms of circRNAs affecting tumor progression and metastasis. What's more, we validated the potential clinical application of circRNAs serving as diagnostic and prognostic biomarker. The discussion and analysis in circRNAs will broaden our knowledge of the pathogenesis of PC and further optimize the current therapies against different condition.